Browse the evidence

The peptide triple agonist GEP44, targeting GLP-1, Y1, and Y2 receptors, promotes profound weight loss and glycemic control in diet-induced obese rats without triggering the nausea or malaise associated with standard GLP-1 receptor agonists.

This research highlights a promising new class of drugs (triple agonists like GEP44) that may offer superior weight loss and blood sugar control compared to current GLP-1 medications, without causing the nausea that often stops people from taking them. However, this is currently only proven in animals, not humans. For now, standard GLP-1s remain the primary option, but patients experiencing intolerable side effects might discuss clinical trials or future availability of these multi-agonists with their healthcare provider.

Co-treatment with omega-3 polyunsaturated fatty acids (EPA, DPA, or DHA) mitigates palmitate-induced lipotoxicity in skeletal muscle cells, preserving cell viability, preventing apoptosis, and maintaining mitochondrial membrane integrity.

In a cellular context, high levels of saturated fats (like palmitate) can damage muscle cells, causing them to die and stop growing. Omega-3 fatty acids (EPA, DHA, DPA) can protect these cells from this damage. Specifically, DPA was found to fully preserve cell viability and mitochondrial integrity, while EPA and DHA offered partial protection. This suggests that adequate omega-3 intake may help counteract some negative effects of high saturated fat diets on muscle health at a cellular level.

Meal timing is not associated with body composition (fat mass, lean mass, or BMI) in young adults, regardless of sex.

Changing when you eat will not directly change your weight or body fat percentage. Focus on total calorie intake and exercise for body composition changes. However, timing may still be useful for metabolic health markers like insulin sensitivity.

GLP-1RAs activate neurons in the paraventricular nucleus (PVH) and ventromedial hypothalamus (VMH) to suppress food intake and increase energy expenditure or thermogenesis.

GLP-1 medications also target other brain regions (PVH and VMH) to suppress food intake and increase energy expenditure. This helps explain why these medications can lead to weight loss even without significant changes in diet or exercise.

Continuing lifestyle interventions (diet/exercise) after stopping AOMs does not prevent significant weight regain, as this subgroup also showed significant regain.

Even if you maintain a healthy diet and exercise routine, stopping anti-obesity medication is likely to lead to weight regain. The biological effects of the medication are significant, and lifestyle changes alone may not be enough to counteract the regain.

Relying solely on Fasting Plasma Glucose (FPG) for diagnosis misses a significant number of diabetes cases in Korean populations; OGTT or HbA1c is required for accurate diagnosis.

If you are Asian or have a lower body weight, a normal fasting blood sugar might not mean you are safe. You may have high blood sugar after eating. Ask your doctor about an OGTT or HbA1c test if you have risk factors.

HbA1c is a valid diagnostic criterion for diabetes (≥6.5%) in Korea, but it should not be used alone due to lower detection rates compared to combined FPG and OGTT.

HbA1c is a convenient test that doesn't require fasting, but it might miss diabetes if used alone. For the most accurate diagnosis, especially if you have conditions like anemia or kidney disease, combine it with fasting glucose or an OGTT.

Macrophage-specific lipoprotein lipase (LPL) promotes atherosclerosis by acting as a bridging molecule for remnant lipoprotein uptake, leading to foam cell formation and plaque progression.

LPL helps clear fat from blood, but in immune cells within artery walls, it helps build plaques. Therapies targeting LPL must distinguish between clearing blood fat (good) and feeding artery plaques (bad).

Dispensing rates for GLP-1 RAs are significantly lower for obesity (AOM) indications compared to diabetes (ADM) indications, with a large gap in 60-day initiation rates.

Even if prescribed, GLP-1 RAs for weight loss are less likely to be filled than those for diabetes, largely due to insurance coverage issues. If you are prescribed an AOM GLP-1 RA, proactively check your insurance coverage and explore assistance programs to ensure you can access the medication.

Dispensing rates for GLP-1 RAs are lower in patients aged 65+ compared to those aged 18-64, particularly for AOM indications.

Older adults (65+) are less likely to fill GLP-1 RA prescriptions for weight loss compared to younger adults, largely due to Medicare not covering these medications. If you are 65 or older, discuss alternative coverage options or patient assistance programs with your healthcare provider.

Triple agonists targeting GLP-1, GIP, and Glucagon receptors improve energy expenditure and restore body weight in diet-induced obesity models more effectively than dual or mono-agonists.

Triple hormone agonists (GLP-1/GIP/Glucagon) are in development and show promise in animal studies for boosting energy expenditure and weight loss beyond what dual agonists achieve. They are not yet standard clinical care.

GIP receptor agonism contributes to insulin sensitivity independently of weight loss by promoting glucose capture in white adipose tissue and catabolism of branched-chain amino acids in brown adipose tissue.

The addition of GIP receptor activation in dual agonists may help improve insulin sensitivity through metabolic pathways in fat tissue, independent of just losing weight.

Reducing saturated fat intake has little or no effect on all-cause mortality, cardiovascular mortality, or cancer deaths in adults.

While reducing saturated fat is excellent for preventing heart attacks and strokes, you should not expect it to drastically extend your lifespan on its own. Focus on the quality of life and prevention of non-fatal cardiovascular events as the primary benefit.

Adjunctive liraglutide 1.8 mg for 6 months following laparoscopic adjustable gastric banding (LAGB) provides no significant additional improvement in HbA1c or body weight compared to LAGB alone, and cessation of therapy leads to significant weight regain and worsening glycemic control relative to placebo.

If you have had a gastric band and are considering adding Liraglutide (Victoza) for 6 months, current evidence suggests it will not provide extra weight loss or blood sugar benefits during that time, and you may regain more weight after stopping it compared to not taking it. This does not rule out other GLP-1 drugs (like Semaglutide) or longer durations, but for this specific protocol, it is not recommended.

Daily consumption of a multi-ingredient supplement (whey protein, creatine, vitamin D, n-3 PUFA) for 7 weeks does not significantly alter resting or acute exercise-stimulated myofibrillar protein synthesis (MyoPS) in overweight older men compared to a control beverage.

For older overweight men, simply adding a multi-ingredient supplement (protein, creatine, vitamins) twice daily for several weeks does not necessarily boost muscle protein synthesis rates beyond what the body naturally does with exercise. Focus on consistent resistance training rather than expecting supplements to automatically amplify muscle growth signals.

A lifestyle pattern characterized by high consumption of food, alcohol, and cigarettes is associated with higher triglycerides, gamma-glutamyl transpeptidase (GTP), and diastolic blood pressure in T2DM patients.

For T2DM patients, high intake of alcohol, cigarettes, and large meals contributes to liver stress and high triglycerides. Reducing these specific behaviors can improve liver enzyme levels and blood pressure, even if blood sugar control remains stable.

Semaglutide therapy in older adults with type 2 diabetes accelerates muscle mass loss and functional decline, with higher doses and lower baseline muscle mass predicting greater loss.

If you are taking Semaglutide and are over 65 with diabetes, monitor your muscle strength. The medication can cause muscle loss, especially at higher doses. To counter this, focus on resistance training and adequate protein intake, and discuss dose adjustments with your doctor if you notice weakness.

Social media platforms (Instagram, TikTok) misrepresent semaglutide by promoting off-label weight loss use while omitting common adverse effects like gastrointestinal disorders, leading to unreflected medication use and supply shortages for indicated patients.

If you are considering semaglutide for weight loss, understand that it is a prescription medication with significant side effects, primarily gastrointestinal issues. Social media often omits these risks. Consult a healthcare provider to ensure it is appropriate for you and to avoid contributing to shortages for diabetic patients.

Enhancing insulin signaling specifically in adipose tissue improves obesity-related metabolic disorders by promoting healthy fat expansion and preventing ectopic fat accumulation, whereas enhancing insulin signaling in the liver exacerbates metabolic dysfunction.

Treating obesity-related metabolic issues requires targeting the right tissue. Simply boosting insulin systemically can be harmful, particularly to the liver. Future therapies must distinguish between adipose tissue (where boosting insulin helps store fat safely) and the liver (where boosting insulin worsens fat accumulation). Current clinical focus remains on lifestyle changes and existing drugs that improve sensitivity, but the research highlights the need for tissue-specific drugs.

Tirzepatide treatment in high-fat diet-induced metabolic dysfunction-associated fatty liver disease (MAFLD) mice significantly reduces hepatic lipid accumulation and liver damage by downregulating fatty acid uptake proteins (Cd36, Fabp2/4) and upregulating cholesterol efflux regulators (Hnf4a, Abcg5, Abcg8).

For individuals with fatty liver disease, tirzepatide (a dual GIP/GLP-1 agonist) has been shown in preclinical models to reduce liver fat and inflammation. It works by decreasing fatty acid uptake and increasing cholesterol excretion. While promising, these results are from mice, and human clinical data is needed to confirm efficacy and safety for liver health specifically.

Laparoscopic sleeve gastrectomy reduces the leptin-to-adiponectin ratio (LAR) in adults with severe obesity, which serves as a marker for improved insulin sensitivity and reduced cardiovascular risk.

For individuals with severe obesity considering sleeve gastrectomy, expect a significant improvement in insulin sensitivity, measured by the leptin-to-adiponectin ratio, within a year. This hormonal shift is a key driver of metabolic health improvement, potentially reducing the need for diabetes medications. While weight loss is substantial, the hormonal changes, particularly increased adiponectin, are critical for long-term metabolic benefits.

Current standard-of-care structured lifestyle modification (500 kcal deficit + 150 min activity) added to obesity pharmacotherapy lacks evidence of improving drug response and may act as a barrier to care by reinforcing stigma.

If you are starting obesity medication, you do not need to complete a mandatory lifestyle program to access or benefit from it. Current evidence does not show that mandatory calorie counting and exercise improve drug results. Focus on your health and well-being; if you choose to make lifestyle changes, do so for yourself, not as a requirement for your medication.

Pharmacological activation of brown adipose tissue (BAT) and induction of 'browning' in white adipose tissue (WAT) via agents such as β3-adrenergic receptor agonists, thyroid receptor agonists, and GLP-1-based multi-agonists enhances energy expenditure and improves metabolic parameters, offering a potential therapeutic avenue for obesity management.

This research suggests that certain medications (like GLP-1 agonists or specific receptor agonists) may help manage obesity not just by suppressing appetite, but by actively turning on your body's internal heating system (brown fat). This process burns energy as heat, which can improve blood sugar and lipid levels. While this might not always lead to massive weight loss on its own, it addresses the metabolic slowdown that often hinders long-term weight management.

Obesity-associated low-grade inflammation and adipose tissue dysfunction can induce resistance to β3-adrenergic receptor agonists (like CL316243) by suppressing β3-AR expression via the EPAC/RAP2A signaling pathway, thereby blunting thermogenic efficacy.

If you have obesity-related inflammation, standard fat-burning medications that target specific receptors (like β3-agonists) might be less effective because your body's inflammatory state can block these receptors. This highlights why some people don't respond to certain treatments and why newer drugs with different mechanisms might be needed.